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ABSTRACT
Some oral manifestations have been observed in patients with coronavirus disease 2019 (COVID-19). However, there is still a question about whether these lesions are due to coronavirus infection or secondary manifestations resulting from patient's stress, medications,
and/or other related immunosuppressive factors and systemic conditions or by the actions of opportunistic infections brought by other viruses, bacteria, and fungi in the oral cavity. There is growing evidence that angiotensin-converting enzyme 2 (ACE2), the main host cell
receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is highly expressed on the cells of the oral mucosal epithelia and of the salivary glands, which may explain the development of dysgeusia in patients with COVID-19. Hence, it is important to
understand if SARS-CoV-2 can infect and replicate in oral cells causing other oral manifestations and lesions. Based on a short review of the literature, this study aims to report on the oral lesions detected in patients diagnosed with COVID-19 from March 2020 to March
2021, focusing on the correlation of clinical and pathological features to analyze the possible effect of the SARS-CoV-2 as the etiological factor.
Correa et. al. Cases

MATERIALS AND METHODS
•
•
•

•

DISCUSSION
Incidence of oral lesions which have the SARS-Cov-2 as their direct
etiological factor remains to be determined. Oral manifestations such as
gustatory disorders and xerostomia have been reported as early symptoms
principally in patients with mild severity condition. A common trend of the
severity and widespread of oral lesions are observed in older patients with
more severe COVID-19 infection. Oral lesions present two well-defined and
distinct patterns, one resembling aphthous-like ulcers in young patients with
mild cases and another with more widespread patterns resembling HSV-1
necrotic ulcers in the more severe and immunosuppressed older individuals.
Prognosis of the oral lesions occurs in parallel with the resolution and the
level of severity of the COVID-19 infection in patients. This leads to
speculate that the development of oral manifestations in these patients may
be directly associated with the COVID-19 infection. Presence of SARS-Cov2 in saliva would induce gustatory disorders and oral lesions development.
This could be influenced by the prolonged presence and load of the virus.
Increase of permeability of the cell walls to foreign pathogens after infection,
especially for herpes viruses (HHS-, HHS-7 and EBV). Interaction of SARSCov-2 and other viruses, bacteria, or fungi may lead to coinfections and oral
lesions development. Systemic conditions and risk factors before the
infection and those derived by the infection as well as the medications that
these patients are taking for the treatment of such conditions or those
administered for the Covid-19 infection management play an important role
in the development of oral lesions. It is speculated that SARS-Cov-2 can
spread internally by swallowing or inhaling infected droplets or cells that
have been shed from the oral cavity. The virus can also spread externally
from infected saliva. Coinfections and comorbidities may worsen especially
for those patients with severe Covid-19 infection because of the lack or
improper oral hygiene during their hospitalizing time. Intraoral lesions often
are misdiagnosed due to the lack of intraoral examinations. Performing
intraoral examinations aids in the detection and diagnosis of many diseases
and health conditions and clinic professionals should overlook its
importance and it seems that the COVID-19 infection is not the exception.

Selected information from PubMed articles and publications from March
2020 to March 2021.
16 sources were selected.
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Experts consulted: Professor Dr. Gwen Cohen-Brown DDS, FAAOMP

INTRODUCTION
People with COVID-19 presents a wide range of symptoms reported ranging
from mild symptoms to severe illness which may appear 2-14 days after
exposure. About half of COVID19 cases present evident oral manifestations
such as taste loss, dry mouth and oral lesions. SARS-CoV-2 uses the ACE2
and TMPRSS proteins as the host entry factors which are detected in the cell
membrane of salivary glands and oral mucosa epithelia. Therefore, there is
the possibility that there is a link between the oral tissues and the virus as the
etiology for oral lesions that COVID-19 patients develop during the time of
infection due to the result of viral binding to the oral epithelial. SGs and
epithelia of the oral cavity could also contribute to its transmission. It is
speculated that saliva from asymptomatic individuals with COVID-19 has the
potential for viral transmission demonstrating a positive correlation between
salivary viral load and taste loss. This is critical because SGs and oral
mucosa are sites of early infection and they could play an important role in
transmitting the virus internally via saliva. This study aims to explain the
possible correlation between SARS-CoV-2 and oral lesions detected in
patients diagnosed with COVID -19 during the time of the pandemic from
March 2020 to March 2020, focusing on the studies that have been
presented in this regard.

RESULTS
• SARS-CoV-2 spike glycoprotein binds to ACE2 and is reported to be
activated by tissue-specific proteases (TMPRSS2, TMPRSS4 and
TMPRSS11D) and endosomal proteases (CTSB, CTSL, BSG and FURIN)
to gain entry for replication.
• ACE2 and TMPRSS markers were detected in eight epithelial clusters of the
oral cavity which are potentially susceptible to infection by SARS-CoV-2.

Figure 2: ACE2 and TMPRSS2 in Diverse Oral Tissue. Source: Huang et. al. (2021)

• The diversity of oral epithelial cells could provide multiple available targets for
viral infection, making the salivary glands and the barrier mucosa of the oral
cavity and oropharynx possible gateways for viral infection, replication and
transmission.
• Interaction between SARS-CoV-2 and ACE2 might disrupt the function of oral
keratinocytes and the epithelial lining of salivary glands ducts, resulting in the
development of gustatory disorders and painful oral mucosal ulcerations and
necrosis.
• The SARS-CoV-2 virus induces lesions in the vessel walls, predisposing to
platelet aggregation and the formation of thrombosis in the microcirculation
possibly causing Microthrombi especially in the sublingual region.
• Lesions can be further exacerbated by increased inflammation and
upregulation in inflammatory markers - cytokines and interleukins initiated by
the SARS CoV-2 virus.
• COVID-19 has been also being suggested to cause dry mouth due to biologic
mechanisms that involves the viral entry into SGs. It seems that the viral
infection of the salivary glands can influence both the quantity and quality of
saliva being produced.
• Two critical questions for SARS-CoV-2 pathogenesis. First, SARS-CoV-2 might
originally infect cells in situ and then be shed into saliva. Second, populations
of shed infected cells might provide binding sites for SARS-CoV-2 and/or act as
carriers to promote viral stability and transmissibility.
Co-morbidities that are supported by meta-analysis/systematic review
*Cancer

Figure 5: Cases 1 to 6 0ral Lesions in COVID-19 Patients. Source: Based on Correa et al information (2021)

Brandao et. al. Cases
Clinical features of the oral ulcers in patients with COVID-19
Patient

Gender

Age

Severity

1

M

81

Severe

Dysgeusia/
Ageusia
Yes

Oral lesion

2

F

71

Severe

Yes

3

F

83

Mild

No

4

M

72

Mild

No

5
6

F
M

32
35

Yes
Yes

7
8

M
M

29
28

Mild
Moderat
e
Mild
Mild

Aphthous-like +
Necrosis
Hemorrhagic
ulcerations with
Necrotic areas
Aphthous-like +
Necrosis
Aphthous-like +
Necrosis
Aphthous-like
Aphthous-like

Yes
Yes

Aphthous-like
Aphthous-like

Onset
(days)
5

Duration

4

>15

2

5

5

7

10
6

5
8

8
8

5
6

Table 1: Clinical Features of the Oral Ulcers in Patients with COVID-19. Source: Based on Brandao et al information (2021)

CONCLUSION
Detailed analysis of the oral mucosal epithelia has allowed to have a better
approach for the oral manifestations of COVID19 in infected individuals
revealing new and important data about the clinical expression of the
disease and its routes of transmission and infection pointing to the
possibility that the mouth plays an important role. It has been proven that
SARS-CoV-2 can infect and replicated in the salivary glands and oral
mucosa epithelia via two key entry factors presented by oral cells: ACE2
receptors and TMPRSS2 enzyme leading to gustatory disorders and
xerostomia as well as a variety of oral lesions. Even though more clinical
evidence and research are needed to confirm the ability of SARS-CoV-2 to
infect the oral tissues and their pathogenic mechanisms in the oral mucosae
the last studies have proven important evidence in this regard.

Co-morbidities that are supported by mostly observational studies
*Children with certain underlying conditions

*Cerebrovascular disease

*Down syndrome

*Chronic kidney disease

*HIV (human immunodeficiency virus)

*COPD (chronic obstructive pulmonary disease)

*Neurologic conditions, including dementia

*Diabetes mellitus, type 1 and type 2
*Heart conditions (heart failure, coronary artery disease, or cardiomyopathies)
*Obesity (BMI ≥30 kg/m2)

*Overweight (BMI ≥25 kg/m2, but <30 kg/m2)
*Lung disease (interstitial lung disease, pulmonary fibrosis, pulmonary hypertension)
*Sickle cell disease

*Pregnancy

*Solid organ or blood stem cell transplantation

*Smoking, current and former

*Substance use disorders
*Use of corticosteroids or other immunosuppressive medications

SARS-CoV-2 RISK
FACTORS
Co-morbidities that are supported by
mostly case series, case reports, or, if
other study design, the sample size is
small (no systematic review or metaanalysis available was available to review)

Co-morbidities that are supported by
mixed evidence

*Cystic fibrosis

*Immune deficiencies

*Thalassemia

*Liver disease

11

*Asthma
*Hypertension
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